Protocol Status: PUBLISHED
Protocol:
Version: 2026.01
Effective Date:
Last Reviewed:
Medical Director Approval:
Clinical Note: This content reflects current GCEMS clinical guidelines as of the dates listed above. If content appears inconsistent with current policy, use the most recent approved guideline and notify leadership for correction.

Combivent

(DuoNeb)

 

GCEMS Protocol:

 

  • Reactive Airway Disease
  • Drowning

 

Indications:

  • Bronchospasm
  • COPD

 

Contraindications:

 

  • Hypersensitivity to Atrovent, Atropine or its derivatives
  • Hypersensitivity to Albuterol

 

Side Effects:

 

  • Tachycardia
  • Palpitations
  • Eye pain
  • Urinary retention
  • UTI Urticaria
  • Bronchitis

 

Adult Dosage:

 

  • 3.5 mg nebulized; may not repeat

 

Pediatric Dosage:

 

  • 3.5 mg nebulized; may not repeat